Mont-Saint-Guibert, Belgium; August 7, 2025, 06:30 pm CET; regulated information – Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on August 5, 2025, of 3,333,333 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 9,216,154.53 EUR and is represented by 44,761,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures – Modified on August 5, 2025, following the capital increase:
| Total amount of share capital (EUR) | 9,216,154.53 |
| Total Number of shares with single voting rights | 35,893,530 |
| Total Number of shares with double voting rights | 8,868,375 |
| Total Number of Shares | 44,761,905 |
| Total of voting rights | 53,630,280 |
| Total number of attributed warrants | 3,856,134 |
| Total number of shares with voting rights that could be created following the exercise of the attributed warrants | 3,856,134 |
| Total number of diluted shares (Outstanding shares + Warrants) | 48,618,039 |
| Total number of diluted shares with voting rights | 57,486,414 |
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Matthew Kane, Chief Executive Officer (CEO): investors@celyad.com.
Further questions about the content of this release can be sent to investors@celyad.com.
